Capstan Medical
Overview
Capstan Medical is a pioneering company in the field of medical technology, focusing on developing minimally invasive, robotic-assisted solutions for heart valve disease. Founded in 2020 and headquartered in Santa Cruz, California, Capstan Medical aims to transform the treatment of structural heart diseases through innovative robotic platforms. The company has raised a total of $150 million, with its most recent Series C funding round amassing $110 million. Maggie Nixon serves as the CEO, and the company was co-founded by Dan Wallace.
Recent Developments
- December 2024: Capstan Medical announced a successful Series C funding round, raising $110 million to advance its pioneering robotic-assisted platform for heart disease treatment. This round was led by Eclipse, with participation from long-standing investors like Yu Galaxy and Intuitive Ventures, and a new investor, Gideon Strategic Partners.
- December 2024: The company gears up for the first-in-human trials of its mitral valve technology scheduled for early 2025, targeting a pivotal trial start in 2026. The tricuspid valve replacement, also under development, aims for similar early-stage trials in the coming months.
- 2024: Throughout the year, Capstan strengthened its leadership team by recruiting Brian King from Intuitive Surgical, demonstrating its commitment to scaling its engineering and regulatory capabilities.
- August 2023: The company secured $31.4 million in a Series B funding round led by Eclipse, indicating its strategic thrust into clinical development and trial expansion phases.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2020 |
| Headquarters | Santa Cruz, California, USA |
| Founders | Maggie Nixon, Dan Wallace |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Eclipse, Yu Galaxy, Intuitive Ventures, Gideon Strategic Partners |
| Industry | Medical Technology, Robotics, Healthcare |
| Number of Employees | Over 75 |
Early History
Capstan Medical commenced operations in 2020, quickly positioning itself as an innovator in the medical devices sector by integrating robotics and heart valve technology. Founded by seasoned entrepreneurs Maggie Nixon and Dan Wallace, the company aimed to revolutionize heart valve intervention. Drawing from Maggie's rich experience at Intuitive Surgical and Dan's expertise in catheter technologies, Capstan developed a unique robotic platform capable of delivering and deploying heart valve implants with precision.
Company Profile and Achievements
Capstan Medical has set its sights on the groundbreaking development of a minimally invasive heart valve intervention platform. The company's primary achievement lies in the creation of its robotic-assisted system capable of performing intricate procedures such as mitral and tricuspid valve replacements.
- Key Milestones:
- 2020: Foundation and initial technological roadmap development.
- 2023: Successful closure of a $31.4 million Series B funding round.
- 2024: A landmark Series C funding raised $110 million, catapulting the company towards pivotal trial phases.
- Innovative Platform: Capstan's robotic platform integrates catheter-based technologies to precisely position valve implants, significantly reducing the invasiveness of traditional heart surgeries.
- Strategic Focus: The emphasis on mitral valves is motivated by the pressing need to address heart valve disease, which affects over seven million patients in the U.S.
Current Operations and Market Position
Capstan Medical continues to innovate in the healthcare field by advancing its robotic-assisted solutions for heart valve disease. The company stresses the importance of expanding treatment options for mitral and tricuspid valve replacements, currently catering to the underserved patient population with limited surgical options.
Capstan is strategically positioned among industry giants like Abbott and Edwards Lifesciences, which leads existing market solutions. Through cutting-edge research and development, Capstan aims to offer safer and more effective alternatives in structural heart disease management.
Conclusion
Capstan Medical has emerged as a beacon of innovation, tasked with delivering less invasive and more effective heart valve disease treatments. By leveraging advanced robotics and catheter technologies, the company is set to play a crucial role in the minimally invasive procedures market. The potential success of its pivotal trials and the subsequent approval by the FDA could significantly affect its market trajectory, promising a transformative impact on the treatment landscape for heart valve diseases.